Further, the most common side effect of anti-CTLA-4 immunotherapy in cancer patients is enterocolitis, most likely due to increased intestinal levels of the pro-inflammatory cytokines IFNγ and IL-17A [11,12]. Here, CTLA4 is linked to cancer.